Clinical trials: Urinary Frequency
Overactive Bladder
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron modified release low dose or high dose tablets…
- Trial name
- VEL-2001 (NCT03594058)
- Testing
- Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose
- Where
- 77 sites in United States
- Volunteers
- 1,413 people
- Sponsor
- Velicept Therapeutics, Inc.
Overactive Bladder, Overactive Bladder Syndrome
INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder
The objective of this research is to perform a non-masked, non-inferiority randomized controlled trial to assess the quality of life (QOL) of women with idiopathic overactive bladder (OAB) before and after treatment with…
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urinary Urge Incontinence, Urinary Bladder, Overactive
- Trial name
- INTENSE (NCT05309993)
- Testing
- PTNS, TENS
- Where
- United States
- Sponsor
- University of New Mexico
Urinary Incontinence, Urinary Incontinence, Urge
Safety and Performance of UCon Patch Electrode
UCon is a medical device for treating the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behavior of the bladder/bowel musculature e.g.…
- Conditions
- Urinary Incontinence, Urinary Incontinence, Urge, Nocturia, Urinary Frequency More Than Once at Night
- Trial name
- NCT06754189
- Testing
- Time Limited stimulation
- Where
- 3 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- InnoCon Medical
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
- Trial name
- NCT01286454
- Testing
- fesoterodine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Prostatitis, Cystitis, Interstitial
Linkage Analysis in Interstitial Cystitis
Urologic pelvic pain syndrome (UCPPS), variably termed painful bladder syndrome/interstitial cystitis (PBS/IC) in females and chronic prostatitis/chronic pelvic pain syndrome in men (CP/CPPS), is a chronic, debilitating clinical…
- Conditions
- Prostatitis, Cystitis, Interstitial, Urinary Bladder, Overactive, Chronic Pelvic Pain Syndrome
- Trial name
- IC (NCT00675298)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Overactive Bladder, Urgency-frequency Syndrome
OAB and the Microbiome
To determine differences in the urinary microbiomes, identified by polymerase change reaction (PCR) (UTIP™), of female patients with urgency and frequency syndrome with or without pelvic pain (Group A) compared to female controls…
- Trial name
- NCT04831801
- Where
- 2 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Miami
Interstitial Cystitis, Bladder Pain Syndrome
Identifying Genetic Causes of IC/BPS
Interstitial cystitis (IC), also called Bladder Pain syndrome (BPS) is a common condition with no known cause or cure. Twin studies and family accounts have suggested that the condition may be genetic or passed down (inherited)…
- Trial name
- NCT00389142
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Boston Children's Hospital
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
The goal of this clinical trial is to retrospectively identify the most prevalent symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women and to evaluate their impact on quality of life.
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause (GSM), Quality of Life
- Trial name
- NCT07737782
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Mucosa Innovations, S.L.
Urge Urinary Incontinence, Urinary Frequency
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
The primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel.
- Trial name
- NCT00909181
- Testing
- Oxybutynin
- Where
- 55 sites in United States
- Volunteers
- 626 people
- Sponsor
- Antares Pharma Inc.
Overactive Bladder
Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
This study will help determine if behavior modification performed in conjunction with oral Vesicare anticholinergic therapy is more effective for treating overactive bladder symptoms than oral Vesicare anticholinergic therapy…
- Trial name
- NCT00821184
- Testing
- Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Lahey Clinic
Urge Incontinence, Urgency-frequency Syndrome
Percutaneous Nerve Evaluation Trial Time
Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998.
- Conditions
- Urge Incontinence, Urgency-frequency Syndrome, Overactive Bladder
- Trial name
- NCT06226220
- Testing
- Sacral neuromodulation
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Urinary Incontinence
Translating Unique Learning for Incontinence Prevention
More than one in three US women suffers from the distressing, embarrassing, and often unreported problem of urinary incontinence (UI). UI severity increases with age and the financial cost exceeds $19 billion per year .
- Trial name
- TULIP (NCT01599715)
- Testing
- Instructional DVD, Bladder Health Class
- Where
- 2 sites in United States
- Volunteers
- 647 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Overactive Bladder Syndrome
Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder.
The main aim of this study, is compare the effectiveness of transcutaneous posterior tibial nerve stimulation versus percutaneous posterior nerve stimulation in patients with overactive bladder.
- Trial name
- NCT04483817
- Testing
- Transcutaneous tibial nerve stimulation, Percutaneous tibial nerve stimulation
- Where
- Spain
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Fisiocore LC,SL
Bladder Cancer, Bladder Neoplasm
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate…
- Conditions
- Bladder Cancer, Bladder Neoplasm, Bladder Tumors, Cancer of Bladder
- Trial name
- RITE-USA (NCT03335059)
- Testing
- Synergo® RITE + MMC
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Medical Enterprises Ltd.
Urinary Incontinence
Bi-Polar Radio-Frequency and Electrical Muscle Stimulation for Symptoms of Mixed Urinary Incontinence (MUI)
The objective of this trial is to evaluate the safety and efficacy of the combined FormaV and VTone Applicators for Symptoms of Mixed Urinary Incontinence.
- Trial name
- NCT05287490
- Testing
- FormaV and VTone
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- InMode MD Ltd.
Benign Prostatic Hyperplasia
A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)
Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control.
- Trial name
- NCT07619105
- Testing
- Vesomni
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Korea, Inc.
Overactive Bladder
Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females
Overactive bladder (OAB) is characterized by urinary urgency with or without urge urinary incontinence, usually with frequency and nocturia, in the absence of urinary tract infection or other obvious pathology.
- Trial name
- NCT07312955
- Testing
- Solifenacin, Tadalafil
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Overactive Bladder
Overactive Bladder Innovative Therapy Trial (OrBIT)
The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).
- Trial name
- OrBIT (NCT00448175)
- Testing
- Urgent PC Neuromodulation System, Tolterodine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Uroplasty, Inc
Overactive Bladder, Urinary Urge Incontinence
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge
- Trial name
- NCT05308979
- Testing
- OnabotulinumtoxinA 100 UNT [Botox]
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Urinary Bladder, Overactive
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
- Trial name
- ARIES (NCT00662909)
- Testing
- Mirabegron
- Where
- 125 sites in United States, Canada
- Volunteers
- 2,149 people
- Sponsor
- Astellas Pharma Inc